# Smith & Nephew share price today (Smith & Nephew plc, SNN)

> Smith & Nephew plc's earnings have grown faster than its share price. Earnings per share grew +52.3% in a year while the price moved −18.1%. SNN · Healthcare · Medical Devices · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/snn

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Turning around, from the last 12 quarters
- Price: $30.17 (−18.1% in a year)
- P/E: 20.2×, over 8.8 years
- Revenue (Jun 2026): $3.1 B (+4.6% on a year ago)
- Profit (Jun 2026): $303 M (+3.4% on a year ago)
- Operating margin: 14.5% (flat on a year ago)
- ROE: 12%, FY25
- ROIC: 8.7%, against a 6.8% cost of capital: +1.9 points

The main question: yearly earnings per share moved +52.3% while the share price moved −18.1%. ## What is the Smith & Nephew share price today? Smith & Nephew plc's share price was $30.17 at the close on 3 November 2026. It has been falling for 11 weeks. That is 2.8% below its average price over the last 200 trading days. In the last 52 weeks it traded between $26 and $37, and at that close it sat 36% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 1 week in a row. Over the last 10 years the share price moved −12% while the S&P 500 moved +255%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Smith & Nephew pay? Smith & Nephew plc paid $0.78 per share over the last four reported quarters. The most recent declaration was $0.16 for Jun 2026. At today's price of $30.17 that is a yield of 2.59%, based on dividends already paid, not a forecast. ## Which stock lists is Smith & Nephew on? Smith & Nephew is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Smith & Nephew profitable? Smith & Nephew plc earned $303 M of net profit in the Jun 2026 quarter, +3.4% on the same quarter a year earlier. That is the 6th quarter in a row of profit growth. Full-year FY25 profit was $625 M. Over 4 years profit has grown 4.5% a year on average. That is 9.8% of the quarter's revenue. The same quarter a year earlier earned $214 M. For the full year, FY25 profit was $625 M (+51.7% on the year before). Why profit moved: revenue changed +4.6% on a year earlier and the margin moved +0.0 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed +56.4% and revenue +5.7%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra dollar of revenue adds more to profit. ## How much revenue does Smith & Nephew make, and is it growing? Smith & Nephew plc reported $3.1 B of revenue in the Jun 2026 quarter, +4.6% on the same quarter a year earlier. That is the 8th quarter in a row with growth on the year before. Over 4 years it has grown 4.3% a year on average. The last full year, FY25, came in at $6.2 B. FY25 revenue was $6.2 B, +6.1% on the year before. Recent pace: the last four quarters grew +5.7% on average, against 4.3% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +11.4%, against +8.8% a year over the last 8 quarters (stabilising); profit over the last 12 months grew +115.3%, against +3.6% a year (accelerating). ## How much of every $100 of sales does Smith & Nephew keep? Smith & Nephew plc's operating margin was 14.5% in the Jun 2026 quarter, about the same as the same quarter a year ago. Over the last four quarters it has moved +2.9 percentage points. Across 5 years it has been between 12.6% and 15.2%. The latest quarter is within that range. In the latest quarter it moved +0.0 percentage points on the same quarter a year ago. Why the margin moved: operating margin changed +2.9 percentage points on the year while gross margin changed +1.1 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Smith & Nephew's profit turning into cash? Over the last 3 years, 222% of Smith & Nephew plc's reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $1.3 B of operating cash against $625 M of profit. After $433 M of spending on assets, $852 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Smith & Nephew's cash go? Smith & Nephew plc does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $1.2 B on assets over the last 3 years. Averaged over those years that is 6.7% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $1.2 B over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Smith & Nephew's P/E ratio, and how does it compare with its own history? Smith & Nephew plc's P/E is 20.2×, with too little history to compare. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved +52.3% while the price moved −18.1%. Earnings did better than the price, which pulled the multiple down within its own range. Where the price move came from: over 5 years the price moved −4.1% a year; about −9.7% a year came from earnings growth and about +5.6 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple. ## Is the Smith & Nephew business getting better or worse? Smith & Nephew plc's business is turning around. EPS growth has swung from −67.3% at its low to +116.1%, improving for 4 quarters in a row, with ROCE steady at 21.2%. This is based on 12 quarters of 4 measures. Why it matters: a turn in growth is often where a bigger change starts. The lines say a turn is forming, so the question is whether the next quarters confirm it. ## How much does Smith & Nephew earn on its capital? Smith & Nephew plc earned a ROE of 12% in FY25. That is up from a low of 4% in FY22. Its return on capital used (ROIC) is 1.9 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 10.1% net margin and 0.59× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 10.1% net margin × 0.59× asset turnover × 1.98× leverage (assets divided by equity) ≈ 11.8% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 8.7% − 6.8% = +1.9 percentage points. The 6.8% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Positive but thin: it creates value with little room for error. ## Does Smith & Nephew have too much debt? Smith & Nephew plc has total debt of $3.8 B against shareholder equity of $5.2 B as of Jun 2026, so its debt is 0.73× its equity. Year by year, that ratio went from 0.60 in FY21 to 0.63 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the Smith & Nephew shareholding pattern? We have no ownership or short-position figures for Smith & Nephew plc, so this section says so rather than fill the gap. At normal trading volumes, closing those positions would take about 3.2 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. ## How far is Smith & Nephew from balance-sheet trouble? For Smith & Nephew plc, the Z-score is 3.26. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 3.26 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Smith & Nephew rank in its industry? 48.1 out of 100, rank 17 of 30 in Medical Devices, with 51% of the evidence available. Smith & Nephew plc scores 48.1 out of 100 against the 30 companies it is compared with in Medical Devices, ranking 17. Some evidence is missing, so the score is pulled toward the middle on purpose. The four parts add up to the total exactly: 16.6 + 13.6 + 10.3 + 7.6 = 48.1. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Smith & Nephew compared with? Smith & Nephew ranks 17 of 30 Medical Devices companies on the 4-Factor Sector Score, with 48.1 out of 100. 1. [DexCom, Inc.](https://www.sectoralpha.in/us/stocks/dxcm) DXCM · losing its lead · Most evidence points up · 81% evidence 74.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.0/35 · Revenue 15.5% · Profit 74.8% · Operating margin change 5.9 points · 83% evidence Capital efficiency 20.9/25 · ROCE 27.8% · Operating margin 24.3% · 76% evidence Valuation 13.6/20 · P/E 26× · PEG 0.66 · 65% evidence Relative strength 11.6/20 · Lead over its industry 2.6% · Lead over S&P 500 8.7% · 1 year 50.9% · 100% evidence · 10 of 12 weeks ahead Exact sum: 28 + 20.9 + 13.6 + 11.6 = 74.1 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Globus Medical, Inc.](https://www.sectoralpha.in/us/stocks/gmed) GMED · basing · Evidence leans up · 81% evidence 63.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.0/35 · Revenue 19.8% · Profit 50.1% · Operating margin change 7.5 points · 83% evidence Capital efficiency 17.5/25 · ROCE 14.6% · Operating margin 24.8% · 76% evidence Valuation 14.9/20 · P/E 20× · PEG 0.4 · 65% evidence Relative strength 3.3/20 · Lead over its industry -15.4% · Lead over S&P 500 -10.3% · 1 year -5.1% · 100% evidence · 0 of 12 weeks ahead Exact sum: 28 + 17.5 + 14.9 + 3.3 = 63.7 · What this means: Earnings are strong; relative strength in its sector is -15.4% and the one-year return is -5.1%. 3. [Boston Scientific Corporation](https://www.sectoralpha.in/us/stocks/bsx) BSX · quiet · Evidence leans up · 81% evidence 61.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.0/35 · Revenue 13.5% · Profit 46.7% · Operating margin change 4.3 points · 83% evidence Capital efficiency 16.3/25 · ROCE 11.4% · Operating margin 22.9% · 76% evidence Valuation 15.6/20 · P/E 17.3× · PEG 0.37 · 65% evidence Relative strength 4.8/20 · Lead over its industry -38.8% · Lead over S&P 500 -35.7% · 1 year -56.5% · 100% evidence · 0 of 12 weeks ahead Exact sum: 25 + 16.3 + 15.6 + 4.8 = 61.7 · What this means: Earnings are strong; relative strength in its sector is -38.8% and the one-year return is -56.5%. 4. [Haemonetics Corporation](https://www.sectoralpha.in/us/stocks/hae) HAE · leader · Evidence leans up · 81% evidence 59.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 10.8/35 · Revenue 0.3% · Profit -40.5% · Operating margin change 0 points · 83% evidence Capital efficiency 15.3/25 · ROCE 11.8% · Operating margin 17.9% · 76% evidence Valuation 13.3/20 · P/E 36.5× · PEG 0.49 · 65% evidence Relative strength 19.7/20 · Lead over its industry 36.9% · Lead over S&P 500 44.6% · 1 year 76% · 100% evidence · 12 of 12 weeks ahead Exact sum: 10.8 + 15.3 + 13.3 + 19.7 = 59.1 · What this means: Relative strength against the index is 44.6%, and revenue and profit growth are weak. 5. [Insulet Corporation](https://www.sectoralpha.in/us/stocks/podd) PODD · turning · Evidence leans up · 71% evidence 58.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.8/35 · Revenue 29.4% · Profit 58.6% · Operating margin change -2.5 points · 83% evidence Capital efficiency 18.9/25 · ROCE 21.3% · Operating margin 16.2% · 76% evidence Valuation 9.3/20 · P/E 28.1× · PEG n/a · 15% evidence Relative strength 6.5/20 · Lead over its industry -31% · Lead over S&P 500 -27.5% · 1 year -51.6% · 100% evidence · 1 of 12 weeks ahead Exact sum: 23.8 + 18.9 + 9.3 + 6.5 = 58.5 · What this means: Earnings are strong; relative strength in its sector is -31% and the one-year return is -51.6%. 6. [Stryker Corporation](https://www.sectoralpha.in/us/stocks/syk) SYK · basing · Evidence leans up · 81% evidence 57.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.6/35 · Revenue 8.5% · Profit 27.8% · Operating margin change 5 points · 83% evidence Capital efficiency 18.8/25 · ROCE 14.9% · Operating margin 27% · 76% evidence Valuation 11.0/20 · P/E 32.4× · PEG 1.16 · 65% evidence Relative strength 4.8/20 · Lead over its industry -15.7% · Lead over S&P 500 -10.7% · 1 year -12.8% · 100% evidence · 1 of 12 weeks ahead Exact sum: 22.6 + 18.8 + 11 + 4.8 = 57.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Glaukos Corporation](https://www.sectoralpha.in/us/stocks/gkos) GKOS · leader · Evidence leans up · 64% evidence 57.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.2/35 · Revenue 41.8% · Profit n/a · Operating margin change 9.8 points · 62% evidence Capital efficiency 3.9/25 · ROCE -9.7% · Operating margin -8.5% · 76% evidence Valuation 11.2/20 · P/E -98.1× · PEG n/a · 15% evidence Relative strength 19.7/20 · Lead over its industry 53.6% · Lead over S&P 500 62.8% · 1 year 177.9% · 100% evidence · 10 of 12 weeks ahead Exact sum: 22.2 + 3.9 + 11.2 + 19.7 = 57 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Medtronic plc](https://www.sectoralpha.in/us/stocks/mdt) MDT · breaking out · Evidence leans up · 85% evidence 55.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.1/35 · Revenue 9.8% · Profit 12.3% · Operating margin change 0.6 points · 95% evidence Capital efficiency 14.3/25 · ROCE 9.4% · Operating margin 19.3% · 76% evidence Valuation 9.3/20 · P/E 20.9× · PEG 1.72 · 65% evidence Relative strength 12.8/20 · Lead over its industry -1.7% · Lead over S&P 500 3.9% · 1 year 7.2% · 100% evidence · 9 of 12 weeks ahead Exact sum: 19.1 + 14.3 + 9.3 + 12.8 = 55.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [STERIS plc](https://www.sectoralpha.in/us/stocks/ste) STE · basing · Evidence leans up · 81% evidence 54.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.7/35 · Revenue 8.3% · Profit 24.7% · Operating margin change 1.4 points · 83% evidence Capital efficiency 15.4/25 · ROCE 12.2% · Operating margin 19.2% · 76% evidence Valuation 12.5/20 · P/E 25.5× · PEG 1 · 65% evidence Relative strength 7.3/20 · Lead over its industry -10.1% · Lead over S&P 500 -4.9% · 1 year -12.3% · 100% evidence · 3 of 12 weeks ahead Exact sum: 19.7 + 15.4 + 12.5 + 7.3 = 54.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Edwards Lifesciences Corporation](https://www.sectoralpha.in/us/stocks/ew) EW · turning · Evidence leans up · 81% evidence 53.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.1/35 · Revenue 14.6% · Profit -75.8% · Operating margin change 1.7 points · 83% evidence Capital efficiency 18.6/25 · ROCE 14.8% · Operating margin 29.8% · 76% evidence Valuation 3.9/20 · P/E 51.8× · PEG 5.03 · 65% evidence Relative strength 13.2/20 · Lead over its industry 0.1% · Lead over S&P 500 6.2% · 1 year 14.2% · 100% evidence · 2 of 12 weeks ahead Exact sum: 18.1 + 18.6 + 3.9 + 13.2 = 53.8 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value. 11. [Koninklijke Philips N.V.](https://www.sectoralpha.in/us/stocks/phg) PHG · turning · Evidence leans up · 71% evidence 52.3 out of 100 Growth Capital Valuation Relative
12. [CONMED Corporation](https://www.sectoralpha.in/us/stocks/cnmd) CNMD · quiet · Evidence leans up · 81% evidence 52.2 out of 100 Growth Capital Valuation Relative
13. [Integer Holdings Corporation](https://www.sectoralpha.in/us/stocks/itgr) ITGR · losing its lead · Too little evidence to rank firmly · 56% evidence 50.8 out of 100 Growth Capital Valuation Relative
14. [iRhythm Holdings, Inc.](https://www.sectoralpha.in/us/stocks/irtc) IRTC · turning · Evidence leans down · 64% evidence 49.4 out of 100 Growth Capital Valuation Relative
15. [Butterfly Network, Inc.](https://www.sectoralpha.in/us/stocks/bfly) BFLY · quiet · Evidence leans down · 61% evidence 48.9 out of 100 Growth Capital Valuation Relative
16. [UFP Technologies, Inc.](https://www.sectoralpha.in/us/stocks/ufpt) UFPT · losing its lead · Evidence leans down · 81% evidence 48.3 out of 100 Growth Capital Valuation Relative
17. Smith & Nephew plc this page SNN · turning · Too little evidence to rank firmly · 51% evidence 48.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 16.6/35 · Revenue n/a · Profit n/a · Operating margin change 0 points · 26% evidence Capital efficiency 13.6/25 · ROCE 10% · Operating margin 14.5% · 76% evidence Valuation 10.3/20 · P/E 20× · PEG n/a · 15% evidence Relative strength 7.6/20 · Lead over its industry -14% · Lead over S&P 500 -8.8% · 1 year -9.2% · 100% evidence · 0 of 12 weeks ahead Exact sum: 16.6 + 13.6 + 10.3 + 7.6 = 48.1 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 18. [LivaNova PLC](https://www.sectoralpha.in/us/stocks/livn) LIVN · turning · Evidence leans down · 64% evidence 47.6 out of 100 Growth Capital Valuation Relative
19. [GE HealthCare Technologies Inc.](https://www.sectoralpha.in/us/stocks/gehc) GEHC · turning · Evidence leans down · 81% evidence 47.3 out of 100 Growth Capital Valuation Relative
20. [Zimmer Biomet Holdings, Inc.](https://www.sectoralpha.in/us/stocks/zbh) ZBH · turning · Evidence leans down · 81% evidence 45.9 out of 100 Growth Capital Valuation Relative
21. [Bruker Corporation](https://www.sectoralpha.in/us/stocks/brkr) BRKR · turning · Evidence leans down · 71% evidence 44.9 out of 100 Growth Capital Valuation Relative
22. [Neogen Corporation](https://www.sectoralpha.in/us/stocks/neog) NEOG · turning · Evidence leans down · 67% evidence 44.8 out of 100 Growth Capital Valuation Relative
23. [Bio-Rad Laboratories, Inc.](https://www.sectoralpha.in/us/stocks/bio) BIO · leader · Evidence leans down · 71% evidence 42.5 out of 100 Growth Capital Valuation Relative
24. [Axogen, Inc.](https://www.sectoralpha.in/us/stocks/axgn) AXGN · turning · Evidence leans down · 64% evidence 42.1 out of 100 Growth Capital Valuation Relative
25. [Establishment Labs Holdings Inc.](https://www.sectoralpha.in/us/stocks/esta) ESTA · basing · Evidence leans down · 61% evidence 40.7 out of 100 Growth Capital Valuation Relative
26. [Inspire Medical Systems, Inc.](https://www.sectoralpha.in/us/stocks/insp) INSP · breaking out · Evidence leans down · 74% evidence 39.4 out of 100 Growth Capital Valuation Relative
27. [NovoCure Limited](https://www.sectoralpha.in/us/stocks/nvcr) NVCR · quiet · Evidence leans down · 61% evidence 37.8 out of 100 Growth Capital Valuation Relative
28. [Penumbra, Inc.](https://www.sectoralpha.in/us/stocks/pen) PEN · turning · Evidence leans down · 81% evidence 35.7 out of 100 Growth Capital Valuation Relative
29. [TransMedics Group, Inc.](https://www.sectoralpha.in/us/stocks/tmdx) TMDX · quiet · Evidence leans down · 71% evidence 35.7 out of 100 Growth Capital Valuation Relative
30. [Abbott Laboratories](https://www.sectoralpha.in/us/stocks/abt) ABT · turning · Most evidence points down · 85% evidence 34.3 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Medical Devices](https://www.sectoralpha.in/us/sectors/medical-devices), all 30 compared on one page. ## Which companies are close to Smith & Nephew in size? Smith & Nephew is the 13th largest of 75 Medical Devices companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Zimmer Biomet Holdings, Inc., Glaukos Corporation and Penumbra, Inc. Just below it: Insulet Corporation, Globus Medical, Inc. and Bio-Rad Laboratories, Inc. ### Medical Devices companies close in size

1. [Zimmer Biomet Holdings, Inc.](https://www.sectoralpha.in/us/stocks/zbh) $18.5 billion
2. [Glaukos Corporation](https://www.sectoralpha.in/us/stocks/gkos) $13.8 billion
3. [Penumbra, Inc.](https://www.sectoralpha.in/us/stocks/pen) $12.6 billion
4. Smith & Nephew plc $12.5 billion
5. [Insulet Corporation](https://www.sectoralpha.in/us/stocks/podd) $10.7 billion
6. [Globus Medical, Inc.](https://www.sectoralpha.in/us/stocks/gmed) $10.7 billion
7. [Bio-Rad Laboratories, Inc.](https://www.sectoralpha.in/us/stocks/bio) $10 billion

[All 75 Medical Devices companies, largest first](https://www.sectoralpha.in/us/sectors/medical-devices#all-companies)

### Companies close in size in other industries

1. [Penumbra, Inc.](https://www.sectoralpha.in/us/stocks/pen) $12.7 billion · Medical Devices
2. [DICK'S Sporting Goods, Inc.](https://www.sectoralpha.in/us/stocks/dks) $12.6 billion · Specialty Retail
3. Smith & Nephew plc $12.6 billion
4. [Essential Utilities, Inc.](https://www.sectoralpha.in/us/stocks/wtrg) $12.6 billion · Utilities - Regulated Water
5. [The Magnum Ice Cream Company N.V.](https://www.sectoralpha.in/us/stocks/micc) $12.6 billion · Packaged Foods

## What else do people ask about Smith & Nephew? ### What were Smith & Nephew's latest quarterly results? Smith & Nephew plc reported revenue of $3.1 B and net profit of $303 M for the Jun 2026 quarter. Revenue rose 4.6% and profit rose 3.4% compared with a year earlier. Earnings per share were $0.35. The operating margin was 14.5%, 0.0 percentage points higher than a year earlier (as of 3 November 2026). ### What is Smith & Nephew's market cap? Smith & Nephew plc's market capitalisation is $12.5 B at a stock price of $30.17. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Smith & Nephew performing? Smith & Nephew plc's share price has been falling for 11 weeks. In its latest quarter, revenue rose 4.6% and profit rose 3.4% compared with a year earlier. Over the past 13 weeks it has done better than the S&P 500, for 1 week running (as of 3 November 2026). ### Will Smith & Nephew's stock price go up? This page does not forecast Smith & Nephew plc's stock price. What it shows instead: the stock price is $30.17, and it has been falling for 11 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Where is Smith & Nephew in its business cycle? Smith & Nephew plc's FY25 operating margin was 14.2%, against a 5-year range of 12.6% to 15.2%: the middle of its own range, neither a peak nor a low. The latest quarter was 14.5%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Smith & Nephew story? The main question: yearly earnings per share moved +52.3% while the share price moved −18.1%. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Smith & Nephew a stock worth studying right now? What the numbers show: Smith & Nephew plc's earnings have grown faster than its share price. Earnings per share grew +52.3% in a year while the price moved −18.1%. The main open question: whether the price catches up with earnings that have already grown. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.